Johnson & Johnson Innovation
Johnson & Johnson (J&J) was founded in 1886 and is based in New Brunswick, NJ, with an Innovation Center in Cambridge, MA. The firm invests in a variety of fields within the life science sector, including medical devices. J&J’s medical device investments are highly varied in both size and structure; the structure may involve milestone payments, or may be an equity investment. J&J is interested in early stage medical device companies located globally.
Thorsten Melcher
New VenturesJVC Investment Partners
JVC Investment Partners is a private investment firm that was founded in 2000 and is based in Chicago, Illinois. The firm focuses on investments in the healthcare industry. The investment size can vary greatly and is very flexible depending on each company’s needs. The firm provides venture capital and growth capital to healthcare companies. For early-stage investments, the firm targets companies that provide solutions for hospital acquired infections, medication errors, healthcare system operational efficiency enhancements and cost reductions, and chronic disease management, and it typically invests equity or convertible preferred equity in post series A rounds. For growth investments, the firm targets companies with compelling products and strong position in niche markets and with an EBITDA in excess of $2 million. The firm primarily invests in companies based in US.
David Jonas
Founder, President & CEOJonathan Jonas
PartnerLymo Investments
Lymo Investments is a multi-family venture fund based in Silicon Valley, CA. The firm is an active investor in the medical device sector, and is interested in opportunities worldwide. Initial investments are typically about $50,000 with the potential for follow-on investments totaling $500,000, and may be structured as equity or as debt. Lymo Ventures does not invest in seed rounds. In the recent past Lymo Investments has allocated new investments at a rate of approximately one every two months. The firm offers support and expertise to portfolio companies but does not seek a board seat.
Norm Gitis
Founder
Mayo Clinic Ventures
Mayo Clinic Ventures serves to commercialize Mayo Clinic technologies for the benefit of patients worldwide while generating revenue to support clinical practice, research and education at Mayo Clinic. The office has licensed hundreds of technologies in the fields of medical devices, diagnostics, therapeutics, and healthcare IT, and has focused efforts in technology-based ventures and start-ups. Mayo Clinic Ventures also has a $20M venture capital fund which is used to spin out companies that are developing products based on Mayo Clinic research.
Kelly Krajnik
Business Development Manager
Med Qiao Group LLC
Jean Yao, PhD, with 20+ years of extended experience in the areas of biology, medical research, and medical industry, has held various positions at Mayo Clinic and University of Minnesota. She funded Med Qiao Group LLC as for the Bridge between US and China in life science. Med Qiao provides business consulting services that include investment funding, market analysis, intellectual property protection, clinical trial arrangement, product approval application, China branch or division establishment as well as marketing, promotion, distribution and onsite manufacturing of medical products.
Jean Yao
Managing PartnerMedForce
Cary Adams
CEOChristian Renaudin
PartnerPBM Capital Group
Jayson Rieger
SVP of Business Development & Portfolio Management
RCT Ventures
RCT Ventures invests in early-stage life science companies including medical devices, drug discovery platforms, and research tools.
Chad Souvignier
Managing DirectorSand Hill Angels
Stephen Pollitt
Board Member Membership ChairSanus Advisory Asia
Sanus Asia is a Singapore based advisory firm providing investment and transaction-related services across Asia with a focus on Healthcare and Life Sciences.
We work with investors and high potential companies to assist growth/development across Asia through capital raising and strategic/operational support.
We seek to identify high potential US/European Medtech and Digital Health companies with near-term commercialisation potential in Asia.
Will also consider earlier stage investments as a principal Angel investor if there is a strong Asian angle to the technology/business model.